The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of TKI and CPI strategies as first-line treatment of patients with advanced renal cell carcinoma: Real-world outcome data from the German research platform CARAT.
 
Peter J. Goebell
Honoraria - Astellas Pharma; AstraZeneca
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca
 
Martin Boegemann
Employment - Janssen; Janssen
Honoraria - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer/Vital; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck; MSD; Novartis; Pfizer; Roche; Sanofi/Aventis
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; ipsen; Janssen-Cilag; Merck; MSD; Novartis; Roche; Sanofi
Research Funding - IPSEN (Inst); Janssen-Cilag
Travel, Accommodations, Expenses - Amgen; Bayer; BMS GmbH & Co. KG; Janssen-Cilag
 
Arnd Nusch
No Relationships to Disclose
 
Viktor Grünwald
Employment - University Hospital Essen
Stock and Other Ownership Interests - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Genmab; MSD
Honoraria - Advanced Accelerator Applications/Novartis; Amgen; Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Cureteq; Debiopharm Group; Eisai; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Oncorena; PCI Biotech; Pfizer; Synthekine
Research Funding - Amgen (Inst); Bicycle Therapeutics (Inst); BMS (Inst); Gilead Sciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Janssen; Merck Serono; Pfizer
 
Lothar Mueller
Honoraria - Octapharm
Travel, Accommodations, Expenses - Octapharm; Pierre Fabre
 
Eyck von der Heyde
No Relationships to Disclose
 
Dietmar Reichert
No Relationships to Disclose
 
Uwe Marc Martens
Leadership - Founder MOLIT Institute GmbH
Stock and Other Ownership Interests - Eli Lilly, Novo Nordisk
Honoraria - Roche
Consulting or Advisory Role - BMS GmbH & Co. KG; Guardant Health; MSD; Pfizer; Pierre Fabre; Roche
Research Funding - Dieter Schwarz Foundation
Travel, Accommodations, Expenses - Pfizer; Pierre Fabre; Roche
 
Carolin Lennartz
No Relationships to Disclose
 
Michaela Koska
No Relationships to Disclose
 
Martina Jänicke
No Relationships to Disclose
 
Karin Potthoff
No Relationships to Disclose
 
Norbert Marschner
Honoraria - Gilead Sciences; MSD; Novartis; Roche
 
Carsten Grüllich
No Relationships to Disclose
 
Michael D. Staehler
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; EMD Serono; EUSA Pharma; Exelixis; Incyte; Ipsen; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Apogepha; AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; EUSA Pharma; Exelixis; Ipsen; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Novartis; Oncorena; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Novartis; Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; EMD Serono; EUSA Pharma; Ipsen; MSD Oncology; Novartis; Pfizer